Last updated: July 31, 2026
Claritin-D 24 Hour is an over-the-counter extended-release combination of loratadine 10 mg and pseudoephedrine sulfate 240 mg. The product is indicated for temporary relief of nasal congestion, sneezing, runny nose, and itchy or watery eyes associated with allergic rhinitis. Its commercial position is stable, but growth is constrained by pseudoephedrine purchase restrictions, generic competition, and consumer migration toward intranasal therapies.
No active late-stage clinical-development program is associated with Claritin-D 24 Hour. The product is a mature OTC medicine supported by legacy pharmacology, bioequivalence, safety, and postmarketing data rather than by a current trial pipeline. Commercial performance should be analyzed as part of the U.S. oral allergy-and-congestion market, not as an innovative clinical asset.
What is Claritin-D 24 Hour and how does it work?
Claritin-D 24 Hour combines two active ingredients with different mechanisms:
| Component |
Strength |
Function |
| Loratadine |
10 mg |
Second-generation H1 antihistamine that reduces histamine-mediated allergy symptoms |
| Pseudoephedrine sulfate |
240 mg extended release |
Sympathomimetic decongestant that reduces nasal mucosal swelling |
The tablet is taken once daily. Loratadine has limited central nervous system penetration compared with older antihistamines, while pseudoephedrine can cause insomnia, nervousness, palpitations, or increased blood pressure.
The principal clinical value is symptom coverage. Loratadine addresses sneezing, rhinorrhea, and ocular symptoms; pseudoephedrine addresses nasal obstruction. Stand-alone loratadine does not provide equivalent congestion relief.
What conditions does Claritin-D 24 Hour treat?
Claritin-D 24 Hour is labeled for temporary relief of symptoms associated with seasonal allergic rhinitis, including:
- Nasal congestion
- Sneezing
- Runny nose
- Itchy nose or throat
- Itchy or watery eyes
The product is not an antibiotic, antiviral, or disease-modifying treatment. It does not treat the underlying cause of allergic rhinitis.
What is the clinical-trial status of Claritin-D 24 Hour?
Claritin-D 24 Hour has no identifiable current Phase 2 or Phase 3 development program. Its clinical evidence base consists primarily of studies conducted before or around its regulatory approval and OTC commercialization, together with postmarketing safety surveillance.
ClinicalTrials.gov lists studies involving loratadine, pseudoephedrine, allergic rhinitis, and related formulations, but these should not be interpreted as an active Claritin-D 24 Hour sponsor program unless the intervention, formulation, and sponsor match the marketed product exactly (National Library of Medicine, 2024).
What clinical evidence supports the product?
The evidence base supports three conclusions:
- Loratadine is effective for common histamine-mediated allergy symptoms.
- Pseudoephedrine improves nasal airflow and relieves congestion.
- The combination provides broader symptom coverage than loratadine alone when congestion is clinically important.
The combination also creates a safety tradeoff. Pseudoephedrine is less suitable for some patients with uncontrolled hypertension, cardiovascular disease, glaucoma, urinary retention, or sensitivity to stimulants. The product label directs consumers to seek medical advice for relevant conditions and medication interactions (DailyMed, 2024).
Are new Claritin-D clinical trials likely?
A new pivotal trial is unlikely under the current OTC framework. The product has an established active-ingredient history, a mature safety profile, and substantial generic competition. New clinical investment would have limited commercial value unless it supported a reformulation, a new delivery system, a pediatric indication, or a differentiated safety or adherence claim.
The more probable evidence activity is postmarketing surveillance, consumer-use research, label maintenance, and bioequivalence work for competing products.
What is the FDA regulatory status of Claritin-D 24 Hour?
Claritin-D 24 Hour is an FDA-regulated OTC drug product. Loratadine and pseudoephedrine are long-established active ingredients. The product is sold under an FDA-approved drug framework and is also subject to OTC labeling, manufacturing, quality, and adverse-event requirements.
Pseudoephedrine has a distinctive regulatory position. In the United States, products containing pseudoephedrine are generally sold from behind the pharmacy counter or through controlled retail systems. The Combat Methamphetamine Epidemic Act imposes sales-record, identification, daily, and monthly purchase controls (U.S. Drug Enforcement Administration, 2024).
What is the Orange Book status of Claritin-D 24 Hour?
Claritin-D 24 Hour is a drug product rather than a biologic. Its relevant FDA regulatory records are associated with the Drug Products and Orange Book framework. The commercial product is not protected by meaningful remaining pioneer exclusivity based on the age of loratadine and pseudoephedrine.
The practical market barrier is regulatory compliance and manufacturing capability, not a current period of brand exclusivity. Generic and store-brand loratadine-pseudoephedrine extended-release products compete with the branded product.
What patents protect Claritin-D 24 Hour?
No commercially material, unexpired compound patent is expected to protect the basic Claritin-D 24 Hour combination. Loratadine and pseudoephedrine are established active ingredients, and the principal product concept predates the current generic market.
Potential historical rights may have covered:
- Loratadine composition of matter
- Pseudoephedrine dosage forms
- Sustained-release delivery
- Combination formulations
- Tablet manufacture
- Dosing schedules
- Allergy-treatment methods
Those rights are distinct from current market exclusivity. Formulation and manufacturing patents may have expired, been abandoned, or become irrelevant where an approved generic can demonstrate pharmaceutical equivalence without infringing a surviving claim.
How strong is the patent estate for Claritin-D 24 Hour?
The patent estate is weak from a present-day commercial-exclusivity perspective.
| Estate category |
Current commercial impact |
| Loratadine composition patents |
Expired or commercially exhausted |
| Pseudoephedrine composition patents |
Expired |
| Combination patents |
Limited practical protection |
| Extended-release formulation patents |
Generally expired or bypassable |
| Method-of-use patents |
Limited value for a mature OTC indication |
| Manufacturing patents |
Potentially relevant only to specific processes |
| Regulatory exclusivity |
No meaningful current barrier expected |
The product’s defensibility comes from brand recognition, retail placement, packaging, consumer familiarity, and supply reliability.
When does Claritin-D 24 Hour lose exclusivity?
Claritin-D 24 Hour has already lost the exclusivity that would normally protect a new prescription or OTC-switch product. Loratadine and pseudoephedrine are mature ingredients, and generic versions have been available for years.
A competitor does not need to wait for a future pioneer patent expiration to enter the active-ingredient market. Entry depends on FDA approval, pharmaceutical equivalence, manufacturing capacity, retailer access, and compliance with pseudoephedrine controls.
Are Paragraph IV challenges relevant?
Paragraph IV litigation is unlikely to be the central market issue for the basic Claritin-D 24 Hour product. A Paragraph IV certification applies when an ANDA applicant challenges a listed patent for an approved reference drug. For a mature combination with limited remaining patent protection, competition is more likely to proceed through ordinary ANDA or other applicable regulatory pathways.
A future Paragraph IV dispute could arise if a sponsor listed a later formulation, delivery system, or method patent. Such a dispute would concern the specific listed patent, not the basic loratadine-pseudoephedrine concept.
What generic entry risks affect Claritin-D 24 Hour?
Generic entry risk is high. The main competitive products are generic loratadine-pseudoephedrine extended-release tablets, often sold under store brands or pharmacy labels.
The principal risks are:
- Price substitution at the pharmacy counter
- Retailer preference for private-label products
- Consumer switching after pharmacist recommendation
- Promotional discounts by generic suppliers
- Product shortages that shift share among manufacturers
- Reduced brand loyalty for a nonprescription medicine
Pseudoephedrine restrictions reduce impulse purchasing and complicate distribution, but they apply to both branded and generic products. They do not create a durable moat for Claritin-D.
What generic launch scenarios are most likely?
| Scenario |
Market effect |
| Stable generic supply |
Gradual erosion of branded unit share |
| Generic price promotion |
Faster retail substitution |
| Generic shortage |
Temporary brand share recovery |
| Strong allergy season |
Category expansion, with most incremental volume captured by low-cost products |
| Weak allergy season |
Greater trade-down pressure |
| Greater use of nasal steroids |
Structural pressure on oral combination products |
A brand can retain a price premium if consumers value the Claritin name, recognize the packaging, or prefer a specific tablet experience. That premium is likely to narrow over time.
How does Claritin-D compare with competing allergy and congestion drugs?
Claritin-D competes across several product categories rather than against one direct substitute.
| Product category |
Main advantage |
Main limitation |
| Claritin-D 24 Hour |
Once-daily antihistamine plus decongestant |
Pseudoephedrine cardiovascular and stimulant risks |
| Generic loratadine-pseudoephedrine |
Lower price with similar active ingredients |
Lower brand recognition |
| Allegra-D 24 Hour |
Fexofenadine plus pseudoephedrine |
Similar decongestant restrictions |
| Zyrtec-D 12 Hour |
Cetirizine plus pseudoephedrine |
Twice-daily dosing and possible sedation |
| Loratadine alone |
Low cost and broad availability |
Does not address congestion adequately |
| Intranasal corticosteroids |
Strong congestion control for allergic rhinitis |
Requires correct, repeated local use |
| Intranasal antihistamines |
Rapid local effect |
Administration inconvenience and taste issues |
| Phenylephrine products |
Easy retail availability |
Reduced perceived efficacy after FDA review of oral efficacy data |
The most direct substitutes are generic loratadine-pseudoephedrine products and other antihistamine-decongestant combinations. Intranasal corticosteroids are the most important therapeutic substitute for persistent nasal congestion.
What is the market outlook for Claritin-D 24 Hour?
The U.S. market outlook is mature to mildly declining in branded units. Revenue can remain stable temporarily through price increases, seasonal demand, and premium positioning, but volume growth is unlikely without a reformulation or new channel strategy.
The market is influenced by:
- Pollen intensity and seasonal allergy severity
- Consumer spending and private-label substitution
- Availability of pseudoephedrine products
- FDA action affecting oral decongestant categories
- Use of nasal corticosteroids
- Retail pharmacy and e-commerce policies
- Brand promotion and shelf placement
Public companies generally do not disclose Claritin-D 24 Hour revenue separately. Brand-level revenue estimates therefore require third-party retail-audit data or company-specific management disclosures. A defensible forecast should avoid assigning a precise current revenue figure without a licensed sell-through dataset.
What is the 2025-2030 revenue projection?
The following index-based projection isolates the product’s likely trajectory without treating undisclosed brand sales as reported revenue. The index sets 2024 branded retail revenue at 100.
| Year |
Base case |
Upside case |
Downside case |
| 2024 |
100 |
100 |
100 |
| 2025 |
99 |
103 |
94 |
| 2026 |
98 |
105 |
89 |
| 2027 |
96 |
107 |
84 |
| 2028 |
94 |
109 |
80 |
| 2029 |
92 |
111 |
76 |
| 2030 |
90 |
113 |
72 |
The base case assumes approximately 2% annual erosion from generic substitution, partially offset by price and mix. The upside case assumes stronger allergy seasons, effective brand promotion, and stable pharmacy-counter access. The downside case assumes faster private-label substitution, increased use of intranasal therapies, and a sustained reduction in oral decongestant demand.
What is the revenue exposure to seasonal allergy trends?
Seasonality is material. Demand generally rises during spring and early summer pollen periods, with regional variation driven by tree, grass, and ragweed pollen. Weather patterns can alter the timing and intensity of demand.
Revenue exposure is more pronounced for Claritin-D than for a chronic prescription medicine because consumers often purchase the product episodically. A severe allergy season can increase category sales without materially improving long-term market share.
Which companies compete with Claritin-D 24 Hour?
Competition comes from brand owners, generic manufacturers, pharmacy chains, and private-label retailers.
Relevant competitive groups include:
- The Claritin brand owner and its U.S. commercial partners
- Manufacturers of generic loratadine-pseudoephedrine
- Brand owners of Allegra-D and Zyrtec-D
- Retail pharmacy chains selling store-brand equivalents
- Producers of intranasal corticosteroids and antihistamines
- Contract manufacturers supplying OTC retailers
The competitive advantage of a generic is usually price. The advantage of Claritin-D is brand recognition and consumer familiarity. The advantage of intranasal therapies is local treatment of nasal symptoms without systemic pseudoephedrine exposure.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate, not high. The product requires controlled extended-release tablet production, reliable sourcing of loratadine and pseudoephedrine sulfate, stability testing, packaging controls, and compliance with pseudoephedrine tracking rules.
The main operational risks are:
- Controlled distribution of pseudoephedrine
- API supply interruptions
- Extended-release dissolution specifications
- Tablet stability and packaging integrity
- Retail inventory restrictions
- State-level pharmacy-counter requirements
- Product diversion and theft controls
These barriers can affect supply continuity, but they do not create strong proprietary protection. A capable generic manufacturer can compete after meeting FDA quality and equivalence requirements.
What is the litigation and settlement outlook?
No major current patent-litigation wave is expected for the basic Claritin-D 24 Hour product. The active ingredient combination is mature, and the commercial dispute profile is more likely to involve:
- Trademark and trade-dress claims
- OTC advertising disputes
- Retail distribution arrangements
- Product liability claims
- Manufacturing or supply contracts
- Labeling and consumer-protection matters
A traditional Hatch-Waxman settlement would be less likely to determine market timing than it would for a recently approved prescription product with several unexpired listed patents.
Key Takeaways
- Claritin-D 24 Hour contains loratadine 10 mg and extended-release pseudoephedrine sulfate 240 mg.
- It has no current late-stage clinical-development program.
- The product is an established OTC medicine supported by legacy clinical evidence and postmarketing safety data.
- Pioneer exclusivity and meaningful basic-combination patent protection have expired.
- Generic entry risk is high, with pharmacy-counter restrictions applying to both brand and generic products.
- Brand revenue is likely to remain stable in the near term but decline gradually through 2030 under the base case.
- The strongest commercial risks are private-label substitution, intranasal-therapy adoption, and pseudoephedrine access restrictions.
- The strongest commercial assets are brand recognition, retail availability, and once-daily combination dosing.
- Manufacturing requirements create operational barriers but do not provide a durable IP moat.
- The most likely legal disputes concern trademarks, advertising, distribution, and product liability rather than major patent settlements.
FAQs About Claritin-D 24 Hour
Is Claritin-D 24 Hour still clinically relevant?
Yes. It remains relevant for consumers who need both allergy relief and systemic nasal decongestion, although many patients with persistent congestion may receive greater benefit from intranasal corticosteroids.
Is Claritin-D 24 Hour stronger than regular Claritin?
For nasal congestion, yes. Regular Claritin contains loratadine without pseudoephedrine. Claritin-D adds a decongestant, but it also has more contraindications and potential stimulant-related adverse effects.
Can generic loratadine-pseudoephedrine replace Claritin-D 24 Hour?
Generally, an FDA-approved generic with the same active ingredients, strength, and extended-release characteristics is the principal therapeutic substitute. Retail availability and pharmacy-counter requirements determine access.
Does Claritin-D 24 Hour have biosimilar competition?
No. Claritin-D is a small-molecule drug, not a biologic. Its competitors are generic drugs and therapeutic substitutes, not biosimilars.
What could materially improve Claritin-D 24 Hour sales?
A differentiated reformulation, improved delivery profile, stronger retail distribution, or a meaningful shift toward consumers seeking oral combination therapy could improve sales. Seasonal demand alone is more likely to create temporary volume increases than sustained share growth.
References
-
DailyMed. (2024). Claritin-D 24 hour: Loratadine and pseudoephedrine sulfate extended-release tablets, prescribing information. U.S. National Library of Medicine.
-
National Library of Medicine. (2024). ClinicalTrials.gov. U.S. Department of Health and Human Services. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Regulatory information for over-the-counter drugs. https://www.fda.gov/drugs
-
U.S. Drug Enforcement Administration. (2024). Retail sales of pseudoephedrine and ephedrine products. U.S. Department of Justice. https://www.dea.gov/press-releases-media-library/publications/chemical-control-program-retail-sales-pseudoephedrine-and-eph
